{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T16:07:55Z","timestamp":1781626075958,"version":"3.54.5"},"reference-count":171,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T00:00:00Z","timestamp":1766448000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T00:00:00Z","timestamp":1766448000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"University of Bergen"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rev Endocr Metab Disord"],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Antipsychotic drugs (APDs) represent the cornerstone of pharmacological treatment for psychotic disorders, primarily exerting their therapeutic effects through dopamine D2 receptor antagonism or partial agonism. Their interaction with additional neurotransmitter systems - particularly serotonergic, histaminergic, cholinergic, and adrenergic receptors - has been implicated in the development of metabolic side effects, including weight gain and increased cardiovascular risk. Notably, APDs with the highest therapeutic efficacy, such as clozapine and olanzapine, are also associated with the greatest risk of metabolic disturbances, indicating a complex relationship between symptom improvement and adverse metabolic outcomes. In this review, we explore current evidence on the role of the hypothalamus in APD-induced obesity, with a focus on region-specific neurobiological mechanisms and pathophysiological pathways. The review also evaluates the effectiveness of existing anti-obesity interventions and discusses how these strategies may mitigate metabolic side effects without compromising antipsychotic efficacy. Furthermore, the review presents emerging therapeutic approaches, including clustered regularly interspaced palindromic repeats (CRISPR)\/Cas9 gene editing, adenoviral interventions, nano therapies, and small extracellular vesicles targeting hypothalamic function.<\/jats:p>","DOI":"10.1007\/s11154-025-10009-2","type":"journal-article","created":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T06:18:37Z","timestamp":1766470717000},"page":"671-685","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["The hypothalamus as a therapeutic target: Towards novel approaches for managing antipsychotic-induced weight gain"],"prefix":"10.1007","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1914-7371","authenticated-orcid":false,"given":"Sayani","family":"Mukherjee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0027-2124","authenticated-orcid":false,"given":"Silje","family":"Skrede","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Fern\u00f8","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,23]]},"reference":[{"issue":"10","key":"10009_CR1","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1176\/appi.ajp.20240738","volume":"181","author":"S Leucht","year":"2024","unstructured":"Leucht S, Priller J, Davis JM. Antipsychotic drugs: a concise review of history, classification, indications, mechanism, efficacy, side effects, dosing, and clinical application. Am J Psychiatry. 2024;181(10):865\u201378.","journal-title":"Am J Psychiatry"},{"issue":"1","key":"10009_CR2","doi-asserted-by":"publisher","DOI":"10.1038\/s41537-021-00171-2","volume":"7","author":"M Sabe","year":"2021","unstructured":"Sabe M, Zhao N, Crippa A, Kaiser S. Antipsychotics for negative and positive symptoms of schizophrenia: dose-response meta-analysis of randomized controlled acute phase trials. NPJ Schizophr. 2021;7(1):43.","journal-title":"NPJ Schizophr"},{"issue":"1","key":"10009_CR3","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/S2215-0366(19)30416-X","volume":"7","author":"T Pillinger","year":"2020","unstructured":"Pillinger T, McCutcheon RA, Vano L, Mizuno Y, Arumuham A, Hindley G, et al. Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis. Lancet Psychiatry. 2020;7(1):64\u201377.","journal-title":"Lancet Psychiatry"},{"issue":"9","key":"10009_CR4","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1016\/j.euroneuro.2017.06.011","volume":"27","author":"Y Zhu","year":"2017","unstructured":"Zhu Y, Li C, Huhn M, Rothe P, Krause M, Bighelli I, et al. How well do patients with a first episode of schizophrenia respond to antipsychotics: a systematic review and meta-analysis. Eur Neuropsychopharmacol. 2017;27(9):835\u201344.","journal-title":"Eur Neuropsychopharmacol"},{"key":"10009_CR5","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.schres.2021.07.009","volume":"235","author":"MF Stromme","year":"2021","unstructured":"Stromme MF, Mellesdal LS, Bartz-Johannesen C, Kroken RA, Krogenes M, Mehlum L, et al. Mortality and non-use of antipsychotic drugs after acute admission in schizophrenia: A prospective total-cohort study. Schizophr Res. 2021;235:29\u201335.","journal-title":"Schizophr Res"},{"issue":"8","key":"10009_CR6","doi-asserted-by":"publisher","first-page":"2575","DOI":"10.1038\/s41380-024-02445-4","volume":"29","author":"CH Vinkers","year":"2024","unstructured":"Vinkers CH, Kupka RW, Penninx BW, Ruhe HG, van Gaalen JM, van Haaren PCF, et al. Discontinuation of psychotropic medication: a synthesis of evidence across medication classes. Mol Psychiatry. 2024;29(8):2575\u201386.","journal-title":"Mol Psychiatry"},{"issue":"1","key":"10009_CR7","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1001\/jamapsychiatry.2024.2890","volume":"82","author":"L Feber","year":"2025","unstructured":"Feber L, Peter NL, Chiocchia V, Schneider-Thoma J, Siafis S, Bighelli I, et al. Antipsychotic drugs and cognitive function: a systematic review and network meta-analysis. JAMA Psychiatr. 2025;82(1):47\u201356.","journal-title":"JAMA Psychiatr"},{"key":"10009_CR8","doi-asserted-by":"publisher","DOI":"10.3389\/fnut.2021.815456","volume":"8","author":"S Mukherjee","year":"2021","unstructured":"Mukherjee S, Skrede S, Milbank E, Andriantsitohaina R, Lopez M, Ferno J. Understanding the effects of antipsychotics on appetite control. Front Nutr. 2021;8:815456.","journal-title":"Front Nutr"},{"key":"10009_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbr.2021.113144","volume":"403","author":"DA Chestnykh","year":"2021","unstructured":"Chestnykh DA, Amato D, Kornhuber J, Muller CP. Pharmacotherapy of schizophrenia: mechanisms of antipsychotic accumulation, therapeutic action and failure. Behav Brain Res. 2021;403:113144.","journal-title":"Behav Brain Res"},{"key":"10009_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2021.101206","volume":"48","author":"GSH Yeo","year":"2021","unstructured":"Yeo GSH, Chao DHM, Siegert AM, Koerperich ZM, Ericson MD, Simonds SE, et al. The melanocortin pathway and energy homeostasis: from discovery to obesity therapy. Mol Metab. 2021;48:101206.","journal-title":"Mol Metab"},{"issue":"4","key":"10009_CR11","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/j.neuron.2017.06.014","volume":"95","author":"ML Andermann","year":"2017","unstructured":"Andermann ML, Lowell BB. Toward a wiring diagram understanding of appetite control. Neuron. 2017;95(4):757\u201378.","journal-title":"Neuron"},{"issue":"1","key":"10009_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.pnpbp.2009.11.009","volume":"34","author":"C Deng","year":"2010","unstructured":"Deng C, Weston-Green K, Huang XF. The role of histaminergic H1 and H3 receptors in food intake: a mechanism for atypical antipsychotic-induced weight gain? Prog Neuropsychopharmacol Biol Psychiatry. 2010;34(1):1\u20134.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"5","key":"10009_CR13","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1111\/cns.13281","volume":"26","author":"XQ Wan","year":"2020","unstructured":"Wan XQ, Zeng F, Huang XF, Yang HQ, Wang L, Shi YC, et al. Risperidone stimulates food intake and induces body weight gain via the hypothalamic arcuate nucleus 5-HT2c receptor-NPY pathway. CNS Neurosci Ther. 2020;26(5):558\u201366.","journal-title":"CNS Neurosci Ther"},{"key":"10009_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbr.2024.114885","volume":"463","author":"X Liu","year":"2024","unstructured":"Liu X, Lan X, Zhang X, Ye H, Shen L, Hu M, et al. Olanzapine attenuates 5-HT2cR and GHSR1a interaction to increase orexigenic hypothalamic NPY: implications for neuronal molecular mechanism of metabolic side effects of antipsychotics. Behav Brain Res. 2024;463:114885.","journal-title":"Behav Brain Res"},{"key":"10009_CR15","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.psyneuen.2017.08.022","volume":"85","author":"M He","year":"2017","unstructured":"He M, Zhang Q, Deng C, Jin T, Song X, Wang H, et al. Time-dependent effects of olanzapine treatment on the expression of histidine decarboxylase, H1 and H3 receptor in the rat brain: the roles in olanzapine-induced obesity. Psychoneuroendocrinology. 2017;85:190\u20139.","journal-title":"Psychoneuroendocrinology"},{"issue":"6","key":"10009_CR16","doi-asserted-by":"publisher","first-page":"e20571","DOI":"10.1371\/journal.pone.0020571","volume":"6","author":"J Ferno","year":"2011","unstructured":"Ferno J, Varela L, Skrede S, Vazquez MJ, Nogueiras R, Dieguez C, et al. Olanzapine-induced hyperphagia and weight gain associate with orexigenic hypothalamic neuropeptide signaling without concomitant AMPK phosphorylation. PLoS ONE. 2011;6(6):e20571.","journal-title":"PLoS ONE"},{"issue":"5","key":"10009_CR17","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/j.psyneuen.2008.01.018","volume":"33","author":"M Han","year":"2008","unstructured":"Han M, Deng C, Burne TH, Newell KA, Huang XF. Short- and long-term effects of antipsychotic drug treatment on weight gain and H1 receptor expression. Psychoneuroendocrinology. 2008;33(5):569\u201380.","journal-title":"Psychoneuroendocrinology"},{"issue":"8","key":"10009_CR18","doi-asserted-by":"publisher","first-page":"e104160","DOI":"10.1371\/journal.pone.0104160","volume":"9","author":"J Lian","year":"2014","unstructured":"Lian J, Huang XF, Pai N, Deng C. Preventing olanzapine-induced weight gain using betahistine: a study in a rat model with chronic olanzapine treatment. PLoS One. 2014;9(8):e104160.","journal-title":"PLoS One"},{"issue":"9","key":"10009_CR19","doi-asserted-by":"publisher","first-page":"3402","DOI":"10.1172\/JCI93362","volume":"127","author":"CC Lord","year":"2017","unstructured":"Lord CC, Wyler SC, Wan R, Castorena CM, Ahmed N, Mathew D, et al. The atypical antipsychotic olanzapine causes weight gain by targeting serotonin receptor 2C. J Clin Invest. 2017;127(9):3402\u20136.","journal-title":"J Clin Invest"},{"key":"10009_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchemneu.2023.102324","volume":"132","author":"M Krogsbaek","year":"2023","unstructured":"Krogsbaek M, Larsen NY, Landau AM, Sanchez C, Nyengaard JR. Changes in hypothalamic mu-opioid receptor expression following acute olanzapine treatment in female rats: implications for feeding behavior. J Chem Neuroanat. 2023;132:102324.","journal-title":"J Chem Neuroanat"},{"issue":"5","key":"10009_CR21","doi-asserted-by":"publisher","first-page":"R1385","DOI":"10.1152\/ajpregu.00030.2008","volume":"295","author":"MJ Barnes","year":"2008","unstructured":"Barnes MJ, Primeaux SD, Bray GA. Food deprivation increases the mRNA expression of micro-opioid receptors in the ventral medial hypothalamus and arcuate nucleus. Am J Physiol Regul Integr Comp Physiol. 2008;295(5):R1385\u201390.","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"issue":"11","key":"10009_CR22","doi-asserted-by":"publisher","first-page":"3317","DOI":"10.1007\/s00213-019-05291-3","volume":"236","author":"M Garriga","year":"2019","unstructured":"Garriga M, Mallorqui A, Serrano L, Rios J, Salamero M, Parellada E, et al. Food craving and consumption evolution in patients starting treatment with clozapine. Psychopharmacology (Berl). 2019;236(11):3317\u201327.","journal-title":"Psychopharmacology (Berl)"},{"key":"10009_CR23","doi-asserted-by":"publisher","first-page":"587486","DOI":"10.3389\/fpsyt.2020.587486","volume":"11","author":"YH Kim","year":"2020","unstructured":"Kim YH, Ryu S, Nam HJ, Kim M, Jhon M, Lee JY, et al. The psychology of food cravings in patients with first-episode psychosis. Front Psychiatry. 2020;11:587486.","journal-title":"Front Psychiatry"},{"issue":"1","key":"10009_CR24","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/S0169-328X(99)00132-1","volume":"70","author":"S Bouret","year":"1999","unstructured":"Bouret S, Prevot V, Croix D, Jegou S, Vaudry H, Stefano GB, et al. Mu-opioid receptor mRNA expression in Proopiomelanocortin neurons of the rat arcuate nucleus. Brain Res Mol Brain Res. 1999;70(1):155\u20138.","journal-title":"Brain Res Mol Brain Res"},{"issue":"2","key":"10009_CR25","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1159\/000054303","volume":"67","author":"V Mitchell","year":"1998","unstructured":"Mitchell V, Prevot V, Beauvillain JC. Distribution and diurnal variations of the mu opioid receptor expression in the arcuate nucleus of the male rat. Neuroendocrinology. 1998;67(2):94\u2013100.","journal-title":"Neuroendocrinology"},{"issue":"6","key":"10009_CR26","doi-asserted-by":"publisher","first-page":"395","DOI":"10.5607\/en23039","volume":"32","author":"W Won","year":"2023","unstructured":"Won W, Kim D, Shin E, Lee CJ. Mapping astrocytic and neuronal mu-opioid receptor expression in various brain regions using MOR-mCherry reporter mouse. Exp Neurobiol. 2023;32(6):395\u2013409.","journal-title":"Exp Neurobiol"},{"issue":"2","key":"10009_CR27","doi-asserted-by":"publisher","first-page":"120","DOI":"10.5607\/en.2018.27.2.120","volume":"27","author":"MH Nam","year":"2018","unstructured":"Nam MH, Han KS, Lee J, Bae JY, An H, Park S, et al. Expression of micro-Opioid receptor in CA1 hippocampal astrocytes. Exp Neurobiol. 2018;27(2):120\u20138.","journal-title":"Exp Neurobiol"},{"key":"10009_CR28","doi-asserted-by":"crossref","unstructured":"Corkrum M, Rothwell PE, Thomas MJ, Kofuji P, Araque A. Opioid-mediated astrocyte-neuron signaling in the nucleus accumbens. Cells. 2019;8(6):586.","DOI":"10.3390\/cells8060586"},{"issue":"1","key":"10009_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2023.113630","volume":"43","author":"N Sayar-Atasoy","year":"2024","unstructured":"Sayar-Atasoy N, Yavuz Y, Laule C, Dong C, Kim H, Rysted J, et al. Opioidergic signaling contributes to food-mediated suppression of AgRP neurons. Cell Rep. 2024;43(1):113630.","journal-title":"Cell Rep"},{"issue":"5","key":"10009_CR30","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.1038\/s41380-023-01981-9","volume":"28","author":"RC Zapata","year":"2023","unstructured":"Zapata RC, Zhang D, Libster A, Porcu A, Montilla-Perez P, Nur A, et al. Nuclear receptor 5A2 regulation of Agrp underlies olanzapine-induced hyperphagia. Mol Psychiatry. 2023;28(5):1857\u201367.","journal-title":"Mol Psychiatry"},{"issue":"6","key":"10009_CR31","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1038\/nn.4011","volume":"18","author":"AS Garfield","year":"2015","unstructured":"Garfield AS, Li C, Madara JC, Shah BP, Webber E, Steger JS, et al. A neural basis for melanocortin-4 receptor-regulated appetite. Nat Neurosci. 2015;18(6):863\u201371.","journal-title":"Nat Neurosci"},{"key":"10009_CR32","doi-asserted-by":"crossref","unstructured":"Li L, Yoo ES, Li X, Wyler SC, Chen X, Wan R et al. The atypical antipsychotic Risperidone targets hypothalamic melanocortin 4 receptors to cause weight gain. J Exp Med. 2021;218(7).","DOI":"10.1084\/jem.20202484"},{"key":"10009_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2025.156415","volume":"174","author":"N Rattanajearakul","year":"2026","unstructured":"Rattanajearakul N, Kondoh K, Fu O, Okamoto S, Kobayashi K, Nakajima KI, et al. Glucoprivation-induced nutrient preference relies on distinct NPY neurons that project to the paraventricular nucleus of the hypothalamus. Metabolism. 2026;174:156415.","journal-title":"Metabolism"},{"key":"10009_CR34","doi-asserted-by":"publisher","first-page":"107225","DOI":"10.1016\/j.psyneuen.2024.107225","volume":"171","author":"M Krogsbaek","year":"2025","unstructured":"Krogsbaek M, Larsen NY, Yarmahmoudi F, Sondergaard J, Landau AM, Sanchez C, et al. Chronic olanzapine treatment leads to increased opioid receptor expression and changes in feeding regulating neurons in the female rat hypothalamus. Psychoneuroendocrinology. 2025;171:107225.","journal-title":"Psychoneuroendocrinology"},{"issue":"3","key":"10009_CR35","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.molmet.2017.01.001","volume":"6","author":"JH Jeong","year":"2017","unstructured":"Jeong JH, Lee DK, Jo YH. Cholinergic neurons in the dorsomedial hypothalamus regulate food intake. Mol Metab. 2017;6(3):306\u201312.","journal-title":"Mol Metab"},{"issue":"7","key":"10009_CR36","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/j.molmet.2014.07.008","volume":"3","author":"K Rezai-Zadeh","year":"2014","unstructured":"Rezai-Zadeh K, Yu S, Jiang Y, Laque A, Schwartzenburg C, Morrison CD, et al. Leptin receptor neurons in the dorsomedial hypothalamus are key regulators of energy expenditure and body weight, but not food intake. Mol Metab. 2014;3(7):681\u201393.","journal-title":"Mol Metab"},{"key":"10009_CR37","doi-asserted-by":"publisher","first-page":"906717","DOI":"10.3389\/fphar.2022.906717","volume":"13","author":"SB Suh","year":"2022","unstructured":"Suh SB, Lee N, Kim J, Kim S, Jang S, Park JK, et al. Metformin ameliorates olanzapine-induced obesity and glucose intolerance by regulating hypothalamic inflammation and microglial activation in female mice. Front Pharmacol. 2022;13:906717.","journal-title":"Front Pharmacol"},{"issue":"4","key":"10009_CR38","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1038\/s42255-025-01252-7","volume":"7","author":"Y Peng","year":"2025","unstructured":"Peng Y, Feng C, Peng S, Wang Y, Zhang Q, Jiao Z, et al. GLP-2 prevents antipsychotics-induced metabolic dysfunction in mice. Nat Metab. 2025;7(4):730\u201341.","journal-title":"Nat Metab"},{"key":"10009_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.neulet.2018.10.015","volume":"726","author":"M Han","year":"2020","unstructured":"Han M, Deng C. BDNF as a pharmacogenetic target for antipsychotic treatment of schizophrenia. Neurosci Lett. 2020;726:133870.","journal-title":"Neurosci Lett"},{"issue":"8041","key":"10009_CR40","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1038\/s41586-024-08098-1","volume":"636","author":"C Kosse","year":"2024","unstructured":"Kosse C, Ivanov J, Knight Z, Pellegrino K, Friedman J. A subcortical feeding circuit linking an interoceptive node to jaw movement. Nature. 2024;636(8041):151\u201361.","journal-title":"Nature"},{"issue":"9","key":"10009_CR41","doi-asserted-by":"publisher","DOI":"10.1111\/eci.12996","volume":"48","author":"M Lopez","year":"2018","unstructured":"Lopez M. Hypothalamic AMPK and energy balance. Eur J Clin Invest. 2018;48(9):e12996.","journal-title":"Eur J Clin Invest"},{"issue":"7","key":"10009_CR42","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1038\/nrendo.2016.67","volume":"12","author":"M Lopez","year":"2016","unstructured":"Lopez M, Nogueiras R, Tena-Sempere M, Dieguez C. Hypothalamic AMPK: a canonical regulator of whole-body energy balance. Nat Rev Endocrinol. 2016;12(7):421\u201332.","journal-title":"Nat Rev Endocrinol"},{"issue":"7","key":"10009_CR43","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1016\/j.tips.2022.04.007","volume":"43","author":"M Lopez","year":"2022","unstructured":"Lopez M. Hypothalamic AMPK as a possible target for energy balance-related diseases. Trends Pharmacol Sci. 2022;43(7):546\u201356.","journal-title":"Trends Pharmacol Sci"},{"key":"10009_CR44","doi-asserted-by":"publisher","first-page":"102091","DOI":"10.1016\/j.molmet.2024.102091","volume":"92","author":"O Freire-Agulleiro","year":"2025","unstructured":"Freire-Agulleiro O, Estevez-Salguero A, Ferreira V, Holleman CL, Garcia-Curras J, Gonzalez-Garcia I, et al. SF1-specific deletion of the energy sensor AMPKgamma2 induces obesity. Mol Metab. 2025;92:102091.","journal-title":"Mol Metab"},{"issue":"6982","key":"10009_CR45","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1038\/nature02440","volume":"428","author":"Y Minokoshi","year":"2004","unstructured":"Minokoshi Y, Alquier T, Furukawa N, Kim YB, Lee A, Xue B, et al. AMP-kinase regulates food intake by responding to hormonal and nutrient signals in the hypothalamus. Nature. 2004;428(6982):569\u201374.","journal-title":"Nature"},{"issue":"9","key":"10009_CR46","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1038\/nm.2207","volume":"16","author":"M Lopez","year":"2010","unstructured":"Lopez M, Varela L, Vazquez MJ, Rodriguez-Cuenca S, Gonzalez CR, Velagapudi VR, et al. Hypothalamic AMPK and fatty acid metabolism mediate thyroid regulation of energy balance. Nat Med. 2010;16(9):1001\u20138.","journal-title":"Nat Med"},{"issue":"9","key":"10009_CR47","doi-asserted-by":"publisher","first-page":"3456","DOI":"10.1073\/pnas.0611417104","volume":"104","author":"SF Kim","year":"2007","unstructured":"Kim SF, Huang AS, Snowman AM, Teuscher C, Snyder SH. From the cover: antipsychotic drug-induced weight gain mediated by Histamine H1 receptor-linked activation of hypothalamic AMP-kinase. Proc Natl Acad Sci U S A. 2007;104(9):3456\u20139.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"10009_CR48","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1017\/S1461145713000862","volume":"17","author":"S Skrede","year":"2014","unstructured":"Skrede S, Martins L, Berge RK, Steen VM, Lopez M, Ferno J. Olanzapine depot formulation in rat: a step forward in modelling antipsychotic-induced metabolic adverse effects. Int J Neuropsychopharmacol. 2014;17(1):91\u2013104.","journal-title":"Int J Neuropsychopharmacol"},{"issue":"12","key":"10009_CR49","doi-asserted-by":"publisher","first-page":"4895","DOI":"10.1210\/en.2014-1326","volume":"155","author":"M He","year":"2014","unstructured":"He M, Zhang Q, Deng C, Wang H, Huang XF. Olanzapine-activated AMPK signaling in the dorsal vagal complex is attenuated by Histamine H1 receptor agonist in female rats. Endocrinology. 2014;155(12):4895\u2013904.","journal-title":"Endocrinology"},{"issue":"12","key":"10009_CR50","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1111\/dom.12148","volume":"15","author":"M Ikegami","year":"2013","unstructured":"Ikegami M, Ikeda H, Ohashi T, Ohsawa M, Ishikawa Y, Kai M, et al. Olanzapine increases hepatic glucose production through the activation of hypothalamic adenosine 5\u2019-monophosphate-activated protein kinase. Diabetes Obes Metab. 2013;15(12):1128\u201335.","journal-title":"Diabetes Obes Metab"},{"key":"10009_CR51","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.psyneuen.2014.01.018","volume":"42","author":"M He","year":"2014","unstructured":"He M, Zhang Q, Deng C, Wang H, Lian J, Huang XF. Hypothalamic histamine H1 receptor-AMPK signaling time-dependently mediates olanzapine-induced hyperphagia and weight gain in female rats. Psychoneuroendocrinology. 2014;42:153\u201364.","journal-title":"Psychoneuroendocrinology"},{"key":"10009_CR52","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2021.119897","volume":"284","author":"DM Samy","year":"2021","unstructured":"Samy DM, Mostafa DK, Abdelmonsif DA, Ismail CA, Hassaan PS. Crosstalk of hypothalamic chemerin, histamine, and AMPK in diet-and olanzapine-induced obesity in rats. Life Sci. 2021;284:119897.","journal-title":"Life Sci"},{"issue":"6","key":"10009_CR53","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1007\/s40263-013-0062-1","volume":"27","author":"M He","year":"2013","unstructured":"He M, Deng C, Huang XF. The role of hypothalamic H1 receptor antagonism in antipsychotic-induced weight gain. CNS Drugs. 2013;27(6):423\u201334.","journal-title":"CNS Drugs"},{"issue":"3","key":"10009_CR54","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1016\/j.celrep.2017.11.102","volume":"22","author":"S Okamoto","year":"2018","unstructured":"Okamoto S, Sato T, Tateyama M, Kageyama H, Maejima Y, Nakata M, et al. Activation of AMPK-regulated CRH neurons in the PVH is sufficient and necessary to induce dietary preference for carbohydrate over fat. Cell Rep. 2018;22(3):706\u201321.","journal-title":"Cell Rep"},{"key":"10009_CR55","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2022.155335","volume":"137","author":"V Ferreira","year":"2022","unstructured":"Ferreira V, Folgueira C, Guillen M, Zubiaur P, Navares M, Sarsenbayeva A, et al. Modulation of hypothalamic AMPK phosphorylation by olanzapine controls energy balance and body weight. Metabolism. 2022;137:155335.","journal-title":"Metabolism"},{"issue":"8","key":"10009_CR56","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1038\/s42255-019-0095-y","volume":"1","author":"JM Friedman","year":"2019","unstructured":"Friedman JM. Leptin and the endocrine control of energy balance. Nat Metab. 2019;1(8):754\u201364.","journal-title":"Nat Metab"},{"issue":"3","key":"10009_CR57","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1055\/s-2000-8451","volume":"33","author":"T Baptista","year":"2000","unstructured":"Baptista T, Lacruz A, de Mendoza S, Mendoza Guillen JM, Silvera R, Angeles F, et al. Body weight gain after administration of antipsychotic drugs: correlation with leptin, insulin and reproductive hormones. Pharmacopsychiatry. 2000;33(3):81\u20138.","journal-title":"Pharmacopsychiatry"},{"key":"10009_CR58","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.psyneuen.2015.09.026","volume":"63","author":"B Stubbs","year":"2016","unstructured":"Stubbs B, Wang AK, Vancampfort D, Miller BJ. Are leptin levels increased among people with schizophrenia versus controls? A systematic review and comparative meta-analysis. Psychoneuroendocrinology. 2016;63:144\u201354.","journal-title":"Psychoneuroendocrinology"},{"key":"10009_CR59","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.schres.2022.02.015","volume":"243","author":"IT Johansen","year":"2022","unstructured":"Johansen IT, Steen NE, Haram M, Rodevand L, Werner MCF, Lunding SH, et al. Sex differences in antipsychotic-related triglyceride levels are associated with metabolic hormone differences in patients with severe mental disorders. Schizophr Res. 2022;243:55\u201363.","journal-title":"Schizophr Res"},{"issue":"2","key":"10009_CR60","doi-asserted-by":"publisher","first-page":"163","DOI":"10.2174\/1871530318666171207142901","volume":"18","author":"G Erzin","year":"2018","unstructured":"Erzin G, Topcuoglu C, Kotan VO, Bayram S, Fountoulakis K. Assessment of irisin, adiponectin and leptin levels in patients with schizophrenia. Endocr Metab Immune Disord Drug Targets. 2018;18(2):163\u20139.","journal-title":"Endocr Metab Immune Disord Drug Targets"},{"issue":"12","key":"10009_CR61","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1016\/j.clinbiochem.2017.02.003","volume":"50","author":"P Srisawasdi","year":"2017","unstructured":"Srisawasdi P, Vanwong N, Hongkaew Y, Puangpetch A, Vanavanan S, Intachak B, et al. Impact of risperidone on leptin and insulin in children and adolescents with autistic spectrum disorders. Clin Biochem. 2017;50(12):678\u201385.","journal-title":"Clin Biochem"},{"issue":"1","key":"10009_CR62","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1002\/mpo.2950150104","volume":"15","author":"T Sawada","year":"1987","unstructured":"Sawada T, Sugimoto T, Tanaka T, Kawakatsu H, Ishii T, Matsumura T, et al. Number and cure rate of neuroblastoma cases detected by the mass screening program in Japan: future aspects. Med Pediatr Oncol. 1987;15(1):14\u20137.","journal-title":"Med Pediatr Oncol"},{"key":"10009_CR63","doi-asserted-by":"publisher","DOI":"10.1016\/j.mce.2022.111828","volume":"561","author":"M Vranic","year":"2023","unstructured":"Vranic M, Ahmed F, Hetty S, Sarsenbayeva A, Ferreira V, Fanni G, et al. Effects of the second-generation antipsychotic drugs aripiprazole and olanzapine on human adipocyte differentiation. Mol Cell Endocrinol. 2023;561:111828.","journal-title":"Mol Cell Endocrinol"},{"issue":"1","key":"10009_CR64","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s12944-020-01203-z","volume":"19","author":"FT Endomba","year":"2020","unstructured":"Endomba FT, Tankeu AT, Nkeck JR, Tochie JN. Leptin and psychiatric illnesses: does leptin play a role in antipsychotic-induced weight gain? Lipids Health Dis. 2020;19(1):22.","journal-title":"Lipids Health Dis"},{"issue":"2","key":"10009_CR65","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1111\/j.1476-5381.2011.01560.x","volume":"165","author":"J Thundyil","year":"2012","unstructured":"Thundyil J, Pavlovski D, Sobey CG, Arumugam TV. Adiponectin receptor signalling in the brain. Br J Pharmacol. 2012;165(2):313\u201327.","journal-title":"Br J Pharmacol"},{"key":"10009_CR66","doi-asserted-by":"publisher","first-page":"30796","DOI":"10.1038\/srep30796","volume":"6","author":"S Suyama","year":"2016","unstructured":"Suyama S, Maekawa F, Maejima Y, Kubota N, Kadowaki T, Yada T. Glucose level determines excitatory or inhibitory effects of adiponectin on arcuate POMC neuron activity and feeding. Sci Rep. 2016;6:30796.","journal-title":"Sci Rep"},{"issue":"1\u20132","key":"10009_CR67","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/s11010-010-0534-2","volume":"344","author":"JP Wen","year":"2010","unstructured":"Wen JP, Liu CE, Hu YT, Chen G, Lin LX. Globular adiponectin regulates energy homeostasis through AMP-activated protein kinase-acetyl-CoA carboxylase (AMPK\/ACC) pathway in the hypothalamus. Mol Cell Biochem. 2010;344(1\u20132):109\u201315.","journal-title":"Mol Cell Biochem"},{"key":"10009_CR68","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.psyneuen.2015.03.012","volume":"56","author":"F Bartoli","year":"2015","unstructured":"Bartoli F, Lax A, Crocamo C, Clerici M, Carra G. Plasma adiponectin levels in schizophrenia and role of second-generation antipsychotics: a meta-analysis. Psychoneuroendocrinology. 2015;56:179\u201389.","journal-title":"Psychoneuroendocrinology"},{"issue":"3","key":"10009_CR69","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1097\/01.jcp.0000218404.64619.52","volume":"26","author":"AA Richards","year":"2006","unstructured":"Richards AA, Hickman IJ, Wang AY, Jones AL, Newell F, Mowry BJ, et al. Olanzapine treatment is associated with reduced high molecular weight adiponectin in serum: a potential mechanism for olanzapine-induced insulin resistance in patients with schizophrenia. J Clin Psychopharmacol. 2006;26(3):232\u20137.","journal-title":"J Clin Psychopharmacol"},{"issue":"1","key":"10009_CR70","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.euroneuro.2011.03.010","volume":"22","author":"M Wampers","year":"2012","unstructured":"Wampers M, Hanssens L, van Winkel R, Heald A, Collette J, Peuskens J, et al. Differential effects of olanzapine and risperidone on plasma adiponectin levels over time: results from a 3-month prospective open-label study. Eur Neuropsychopharmacol. 2012;22(1):17\u201326.","journal-title":"Eur Neuropsychopharmacol"},{"key":"10009_CR71","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.jpsychires.2019.06.011","volume":"117","author":"EE Lee","year":"2019","unstructured":"Lee EE, Sears DD, Liu J, Jin H, Tu XM, Eyler LT, et al. A novel biomarker of cardiometabolic pathology in schizophrenia? J Psychiatr Res. 2019;117:31\u20137.","journal-title":"J Psychiatr Res"},{"issue":"5","key":"10009_CR72","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1016\/j.cmet.2016.04.011","volume":"23","author":"JH Stern","year":"2016","unstructured":"Stern JH, Rutkowski JM, Scherer PE. Adiponectin, leptin, and fatty acids in the maintenance of metabolic homeostasis through adipose tissue crosstalk. Cell Metab. 2016;23(5):770\u201384.","journal-title":"Cell Metab"},{"issue":"1","key":"10009_CR73","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.bbrc.2009.02.131","volume":"382","author":"M Awazawa","year":"2009","unstructured":"Awazawa M, Ueki K, Inabe K, Yamauchi T, Kaneko K, Okazaki Y, et al. Adiponectin suppresses hepatic SREBP1c expression in an AdipoR1\/LKB1\/AMPK dependent pathway. Biochem Biophys Res Commun. 2009;382(1):51\u20136.","journal-title":"Biochem Biophys Res Commun"},{"issue":"5","key":"10009_CR74","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/sj.tpj.6500323","volume":"5","author":"J Ferno","year":"2005","unstructured":"Ferno J, Raeder MB, Vik-Mo AO, Skrede S, Glambek M, Tronstad KJ, et al. Antipsychotic drugs activate SREBP-regulated expression of lipid biosynthetic genes in cultured human glioma cells: a novel mechanism of action? Pharmacogenomics J. 2005;5(5):298\u2013304.","journal-title":"Pharmacogenomics J"},{"issue":"1","key":"10009_CR75","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/s00213-008-1370-x","volume":"203","author":"J Ferno","year":"2009","unstructured":"Ferno J, Vik-Mo AO, Jassim G, Havik B, Berge K, Skrede S, et al. Acute clozapine exposure in vivo induces lipid accumulation and marked sequential changes in the expression of SREBP, PPAR, and LXR target genes in rat liver. Psychopharmacology. 2009;203(1):73\u201384.","journal-title":"Psychopharmacology"},{"key":"10009_CR76","doi-asserted-by":"crossref","unstructured":"Ferreira V, Folgueira C, Garc\u00eda-Altares M, Guill\u00e9n M, Ru\u00edz-Rosario M, DiNunzio G et al. Hypothalamic JNK1-hepatic fatty acid synthase axis mediates a metabolic rewiring that prevents hepatic steatosis in male mice treated with olanzapine via intraperitoneal: additional effects of PTP1B Inhibition. Redox Biol. 2023;63:102741.","DOI":"10.1016\/j.redox.2023.102741"},{"issue":"1","key":"10009_CR77","doi-asserted-by":"publisher","first-page":"49","DOI":"10.2741\/3675","volume":"16","author":"J Ferno","year":"2011","unstructured":"Ferno J, Skrede S, Vik-Mo AO, Jassim G, Le Hellard S, Steen VM. Lipogenic effects of psychotropic drugs: focus on the SREBP system. Front Biosci (Landmark Ed). 2011;16(1):49\u201360.","journal-title":"Front Biosci (Landmark Ed)"},{"issue":"6","key":"10009_CR78","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/j.euroneuro.2016.07.011","volume":"27","author":"VM Steen","year":"2017","unstructured":"Steen VM, Skrede S, Polushina T, Lopez M, Andreassen OA, Ferno J, et al. Genetic evidence for a role of the SREBP transcription system and lipid biosynthesis in schizophrenia and antipsychotic treatment. Eur Neuropsychopharmacol. 2017;27(6):589\u201398.","journal-title":"Eur Neuropsychopharmacol"},{"issue":"2","key":"10009_CR79","doi-asserted-by":"publisher","first-page":"150","DOI":"10.3109\/07853890.2014.919727","volume":"47","author":"C Contreras","year":"2015","unstructured":"Contreras C, Gonzalez F, Ferno J, Dieguez C, Rahmouni K, Nogueiras R, et al. The brain and brown fat. Ann Med. 2015;47(2):150\u201368.","journal-title":"Ann Med"},{"issue":"15","key":"10009_CR80","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1056\/NEJMoa0810780","volume":"360","author":"AM Cypess","year":"2009","unstructured":"Cypess AM, Lehman S, Williams G, Tal I, Rodman D, Goldfine AB, et al. Identification and importance of brown adipose tissue in adult humans. N Engl J Med. 2009;360(15):1509\u201317.","journal-title":"N Engl J Med"},{"key":"10009_CR81","doi-asserted-by":"publisher","first-page":"105775","DOI":"10.1016\/j.psyneuen.2022.105775","volume":"142","author":"PY Chen","year":"2022","unstructured":"Chen PY, Chiu CC, Hsieh TH, Liu YR, Chen CH, Huang CY, et al. The relationship of antipsychotic treatment with reduced brown adipose tissue activity in patients with schizophrenia. Psychoneuroendocrinology. 2022;142:105775.","journal-title":"Psychoneuroendocrinology"},{"issue":"8","key":"10009_CR82","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.1016\/j.celrep.2016.07.045","volume":"16","author":"L Martins","year":"2016","unstructured":"Martins L, Seoane-Collazo P, Contreras C, Gonzalez-Garcia I, Martinez-Sanchez N, Gonzalez F, et al. A functional link between AMPK and orexin mediates the effect of BMP8B on energy balance. Cell Rep. 2016;16(8):2231\u201342.","journal-title":"Cell Rep"},{"key":"10009_CR83","doi-asserted-by":"publisher","first-page":"1001919","DOI":"10.3389\/fphar.2022.1001919","volume":"13","author":"X Chen","year":"2022","unstructured":"Chen X, Liu L, Zeng Y, Li D, Liu X, Hu C. Olanzapine induces weight gain in offspring of prenatally exposed poly I:C rats by reducing brown fat thermogenic activity. Front Pharmacol. 2022;13:1001919.","journal-title":"Front Pharmacol"},{"key":"10009_CR84","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2022.121111","volume":"310","author":"J Ren","year":"2022","unstructured":"Ren J, Wang J, Guo X, Zhang W, Chen Y, Gao A. Lnc-TC\/miR-142-5p\/CUL4B signaling axis promoted cell ferroptosis to participate in benzene hematotoxicity. Life Sci. 2022;310:121111.","journal-title":"Life Sci"},{"issue":"5","key":"10009_CR85","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbadis.2024.167227","volume":"1870","author":"V Ferreira","year":"2024","unstructured":"Ferreira V, Folgueira C, Montes-San Lorenzo A, Rodriguez-Lopez A, Gonzalez-Iglesias E, Zubiaur P, et al. Estrogens prevent the hypothalamus-periphery crosstalk induced by olanzapine intraperitoneal treatment in female mice: effects on brown\/beige adipose tissues and liver. Biochimica et Biophysica Acta (BBA). 2024;1870(5):167227.","journal-title":"Biochimica et Biophysica Acta (BBA)"},{"issue":"12","key":"10009_CR86","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1093\/ijnp\/pyx073","volume":"20","author":"S Skrede","year":"2017","unstructured":"Skrede S, Gonzalez-Garcia I, Martins L, Berge RK, Nogueiras R, Tena-Sempere M, et al. Lack of ovarian secretions reverts the anabolic action of olanzapine in female rats. Int J Neuropsychopharmacol. 2017;20(12):1005\u201312.","journal-title":"Int J Neuropsychopharmacol"},{"issue":"6","key":"10009_CR87","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1016\/j.euroneuro.2015.03.002","volume":"25","author":"J Fern\u00f8","year":"2015","unstructured":"Fern\u00f8 J, Ersland KM, Duus IH, Gonz\u00e1lez-Garc\u00eda I, Fossan KO, Berge RK, et al. Olanzapine depot exposure in male rats: dose-dependent lipogenic effects without concomitant weight gain. Eur Neuropsychopharmacol. 2015;25(6):923\u201332.","journal-title":"Eur Neuropsychopharmacol"},{"issue":"1","key":"10009_CR88","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.cmet.2024.11.002","volume":"37","author":"AM Cypess","year":"2025","unstructured":"Cypess AM, Cannon B, Nedergaard J, Kazak L, Chang DC, Krakoff J, et al. Emerging debates and resolutions in brown adipose tissue research. Cell Metab. 2025;37(1):12\u201333.","journal-title":"Cell Metab"},{"issue":"12","key":"10009_CR89","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0112276","volume":"9","author":"J Bruins","year":"2014","unstructured":"Bruins J, Jorg F, Bruggeman R, Slooff C, Corpeleijn E, Pijnenborg M. The effects of lifestyle interventions on (long-term) weight management, cardiometabolic risk and depressive symptoms in people with psychotic disorders: a meta-analysis. PLoS One. 2014;9(12):e112276.","journal-title":"PLoS One"},{"key":"10009_CR90","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2020.577691","volume":"11","author":"J Smith","year":"2020","unstructured":"Smith J, Griffiths LA, Band M, Hird-Smith R, Williams B, Bold J, et al. Early intervention in psychosis: effectiveness and implementation of a combined exercise and health behavior intervention within routine care. Front Endocrinol (Lausanne). 2020;11:577691.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"6","key":"10009_CR91","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1080\/17461391.2013.862871","volume":"14","author":"I Giannopoulou","year":"2014","unstructured":"Giannopoulou I, Botonis P, Kostara C, Skouroliakou M. Diet and exercise effects on aerobic fitness and body composition in seriously mentally ill adults. Eur J Sport Sci. 2014;14(6):620\u20137.","journal-title":"Eur J Sport Sci"},{"key":"10009_CR92","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1016\/j.schres.2018.12.021","volume":"210","author":"AJ Romain","year":"2019","unstructured":"Romain AJ, Fankam C, Karelis AD, Letendre E, Mikolajczak G, Stip E, et al. Effects of high intensity interval training among overweight individuals with psychotic disorders: A randomized controlled trial. Schizophr Res. 2019;210:278\u201386.","journal-title":"Schizophr Res"},{"issue":"1","key":"10009_CR93","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1017\/S1461145713000795","volume":"17","author":"HN Boyda","year":"2014","unstructured":"Boyda HN, Ramos-Miguel A, Procyshyn RM, Topfer E, Lant N, Choy HH, et al. Routine exercise ameliorates the metabolic side-effects of treatment with the atypical antipsychotic drug olanzapine in rats. Int J Neuropsychopharmacol. 2014;17(1):77\u201390.","journal-title":"Int J Neuropsychopharmacol"},{"issue":"5","key":"10009_CR94","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1038\/mp.2010.33","volume":"16","author":"VL Albaugh","year":"2011","unstructured":"Albaugh VL, Judson JG, She P, Lang CH, Maresca KP, Joyal JL, et al. Olanzapine promotes fat accumulation in male rats by decreasing physical activity, repartitioning energy and increasing adipose tissue lipogenesis while impairing lipolysis. Mol Psychiatry. 2011;16(5):569\u201381.","journal-title":"Mol Psychiatry"},{"issue":"1","key":"10009_CR95","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1038\/s41598-018-19260-x","volume":"8","author":"LN Castellani","year":"2018","unstructured":"Castellani LN, Peppler WT, Miotto PM, Bush N, Wright DC. Exercise protects against Olanzapine-induced hyperglycemia in male C57BL\/6J mice. Sci Rep. 2018;8(1):772.","journal-title":"Sci Rep"},{"issue":"8","key":"10009_CR96","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1080\/13557858.2017.1390552","volume":"24","author":"DE Jimenez","year":"2019","unstructured":"Jimenez DE, Thomas L, Bartels SJ. The role of serious mental illness in motivation, participation and adoption of health behavior change among obese\/sedentary Latino adults. Ethn Health. 2019;24(8):889\u201396.","journal-title":"Ethn Health"},{"key":"10009_CR97","doi-asserted-by":"publisher","first-page":"846880","DOI":"10.3389\/fendo.2022.846880","volume":"13","author":"P Dimitri","year":"2022","unstructured":"Dimitri P. Treatment of acquired hypothalamic obesity: now and the future. Front Endocrinol (Lausanne). 2022;13:846880.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"7","key":"10009_CR98","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.1007\/s11695-023-06627-x","volume":"33","author":"M Hany","year":"2023","unstructured":"Hany M, Aboudeeb MF, Shapiro-Koss C, Agayby ASS, Torensma B. Safety and effect of bariatric metabolic surgeries for psychiatric patients with obesity: a retrospective matched case-control trial. Obes Surg. 2023;33(7):2115\u201324.","journal-title":"Obes Surg"},{"issue":"4","key":"10009_CR99","doi-asserted-by":"publisher","DOI":"10.1111\/cob.12373","volume":"10","author":"KJ Vermeer","year":"2020","unstructured":"Vermeer KJ, Monpellier VM, Cahn W, Janssen IMC. Bariatric surgery in patients with psychiatric comorbidity: significant weight loss and improvement of physical quality of life. Clin Obes. 2020;10(4):e12373.","journal-title":"Clin Obes"},{"issue":"3","key":"10009_CR100","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1192\/bjb.2022.31","volume":"47","author":"C Pressanto","year":"2023","unstructured":"Pressanto C, Scholtz S, Ali N. Obesity and bariatric surgery in adults living with severe mental illness: perceptions and clinical challenges. BJPsych Bull. 2023;47(3):165\u201371.","journal-title":"BJPsych Bull"},{"issue":"1","key":"10009_CR101","doi-asserted-by":"publisher","first-page":"11","DOI":"10.2337\/cd18-0105","volume":"37","author":"A American Diabetes","year":"2019","unstructured":"American Diabetes A. Standards of medical care in Diabetes-2019 abridged for primary care providers. Clin Diabetes. 2019;37(1):11\u201334.","journal-title":"Clin Diabetes"},{"issue":"4","key":"10009_CR102","doi-asserted-by":"publisher","first-page":"731","DOI":"10.2337\/dc11-1299","volume":"35","author":"Diabetes Prevention Program Research G","year":"2012","unstructured":"Diabetes Prevention Program Research G. Long-term safety, tolerability, and weight loss associated with Metformin in the diabetes prevention program outcomes study. Diabetes Care. 2012;35(4):731\u20137.","journal-title":"Diabetes Care"},{"issue":"1","key":"10009_CR103","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1186\/s12888-016-1049-5","volume":"16","author":"VA de Silva","year":"2016","unstructured":"de Silva VA, Suraweera C, Ratnatunga SS, Dayabandara M, Wanniarachchi N, Hanwella R. Metformin in prevention and treatment of antipsychotic induced weight gain: a systematic review and meta-analysis. BMC Psychiatry. 2016;16(1):341.","journal-title":"BMC Psychiatry"},{"issue":"2","key":"10009_CR104","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1007\/s13679-019-00335-3","volume":"8","author":"A Yerevanian","year":"2019","unstructured":"Yerevanian A, Soukas AA. Metformin: mechanisms in human obesity and weight loss. Curr Obes Rep. 2019;8(2):156\u201364.","journal-title":"Curr Obes Rep"},{"issue":"2","key":"10009_CR105","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1210\/en.2006-1237","volume":"148","author":"C Chau-Van","year":"2007","unstructured":"Chau-Van C, Gamba M, Salvi R, Gaillard RC, Pralong FP. Metformin inhibits adenosine 5\u2019-monophosphate-activated kinase activation and prevents increases in neuropeptide Y expression in cultured hypothalamic neurons. Endocrinology. 2007;148(2):507\u201311.","journal-title":"Endocrinology"},{"issue":"4","key":"10009_CR106","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1038\/s42255-024-00999-9","volume":"6","author":"S Xiao","year":"2024","unstructured":"Xiao S, Li VL, Lyu X, Chen X, Wei W, Abbasi F, et al. Lac-Phe mediates the effects of Metformin on food intake and body weight. Nat Metab. 2024;6(4):659\u201369.","journal-title":"Nat Metab"},{"key":"10009_CR107","doi-asserted-by":"crossref","unstructured":"Luo C, Wang X, Huang H, Mao X, Zhou H, Liu Z. Effect of metformin on antipsychotic-induced metabolic dysfunction: the potential role of Gut-Brain axis. Front Pharmacol. 2019;10(9):371.","DOI":"10.3389\/fphar.2019.00371"},{"issue":"5","key":"10009_CR108","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1007\/s00213-018-5102-6","volume":"236","author":"K Skonieczna-\u017bydecka","year":"2018","unstructured":"Skonieczna-\u017bydecka K, \u0141oniewski I, Misera A, Stachowska E, Maciejewska D, Marlicz W, et al. Second-generation antipsychotics and metabolism alterations: a systematic review of the role of the gut microbiome. Psychopharmacology. 2018;236(5):1491\u2013512.","journal-title":"Psychopharmacology"},{"issue":"3","key":"10009_CR109","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1007\/s00125-015-3844-9","volume":"59","author":"LJ McCreight","year":"2016","unstructured":"McCreight LJ, Bailey CJ, Pearson ER. Metformin and the gastrointestinal tract. Diabetologia. 2016;59(3):426\u201335.","journal-title":"Diabetologia"},{"issue":"2","key":"10009_CR110","doi-asserted-by":"publisher","first-page":"106","DOI":"10.7570\/jomes23032","volume":"32","author":"E Jeon","year":"2023","unstructured":"Jeon E, Lee KY, Kim KK. Approved anti-obesity medications in 2022 KSSO guidelines and the promise of phase 3 clinical trials: anti-obesity drugs in the sky and on the horizon. J Obes Metab Syndr. 2023;32(2):106\u201320.","journal-title":"J Obes Metab Syndr"},{"issue":"1","key":"10009_CR111","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-024-01931-z","volume":"9","author":"Z Zheng","year":"2024","unstructured":"Zheng Z, Zong Y, Ma Y, Tian Y, Pang Y, Zhang C, et al. Glucagon-like peptide-1 receptor: mechanisms and advances in therapy. Signal Transduct Target Ther. 2024;9(1):234.","journal-title":"Signal Transduct Target Ther"},{"issue":"6707","key":"10009_CR112","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1126\/science.adj2537","volume":"385","author":"KS Kim","year":"2024","unstructured":"Kim KS, Park JS, Hwang E, Park MJ, Shin HY, Lee YH, et al. GLP-1 increases preingestive satiation via hypothalamic circuits in mice and humans. Science. 2024;385(6707):438\u201346.","journal-title":"Science"},{"issue":"7","key":"10009_CR113","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1016\/j.cmet.2022.06.002","volume":"34","author":"M Imbernon","year":"2022","unstructured":"Imbernon M, Saponaro C, Helms HCC, Duquenne M, Fernandois D, Deligia E, et al. Tanycytes control hypothalamic liraglutide uptake and its anti-obesity actions. Cell Metab. 2022;34(7):1054\u201363. e7.","journal-title":"Cell Metab"},{"issue":"1","key":"10009_CR114","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1186\/s12888-024-06317-7","volume":"24","author":"B Campforts","year":"2024","unstructured":"Campforts B, Drukker M, van Amelsvoort T, Bak M. Management of obesity with semaglutide or Metformin in patients with antipsychotic-induced weight gain (MOSA): a non-randomised open-label pilot study. BMC Psychiatry. 2024;24(1):865.","journal-title":"BMC Psychiatry"},{"issue":"7","key":"10009_CR115","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1001\/jamapsychiatry.2017.1220","volume":"74","author":"JR Larsen","year":"2017","unstructured":"Larsen JR, Vedtofte L, Jakobsen MSL, Jespersen HR, Jakobsen MI, Svensson CK, et al. Effect of liraglutide treatment on prediabetes and overweight or obesity in Clozapine- or Olanzapine-Treated patients with schizophrenia spectrum disorder: a randomized clinical trial. JAMA Psychiatry. 2017;74(7):719\u201328.","journal-title":"JAMA Psychiatry"},{"issue":"1","key":"10009_CR116","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1111\/acps.12982","volume":"139","author":"CK Svensson","year":"2019","unstructured":"Svensson CK, Larsen JR, Vedtofte L, Jakobsen MSL, Jespersen HR, Jakobsen MI, et al. One-year follow-up on liraglutide treatment for prediabetes and overweight\/obesity in clozapine- or olanzapine-treated patients. Acta Psychiatr Scand. 2019;139(1):26\u201336.","journal-title":"Acta Psychiatr Scand"},{"issue":"2","key":"10009_CR117","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1111\/dom.13522","volume":"21","author":"D Siskind","year":"2019","unstructured":"Siskind D, Hahn M, Correll CU, Fink-Jensen A, Russell AW, Bak N, et al. Glucagon-like peptide-1 receptor agonists for antipsychotic-associated cardio-metabolic risk factors: a systematic review and individual participant data meta-analysis. Diabetes Obes Metab. 2019;21(2):293\u2013302.","journal-title":"Diabetes Obes Metab"},{"issue":"7","key":"10009_CR118","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/S2215-0366(25)00129-4","volume":"12","author":"D Siskind","year":"2025","unstructured":"Siskind D, Baker A, Arnautovska U, Warren N, Russell A, DeMonte V, et al. Efficacy and safety of semaglutide versus placebo for people with schizophrenia on clozapine with obesity (COaST): a phase 2, multi-centre, participant and investigator- blinded, randomised controlled trial in Australia. Lancet Psychiatry. 2025;12(7):493\u2013503.","journal-title":"Lancet Psychiatry"},{"issue":"2","key":"10009_CR119","doi-asserted-by":"publisher","DOI":"10.3892\/etm.2025.12912","volume":"30","author":"SS Alotaibi","year":"2025","unstructured":"Alotaibi SS, Eldrehmy EH, Albogami SM, Alkhedaide A, Dahab O. Advancements and challenges in the management of obesity using pharmacotherapy (Review). Exp Ther Med. 2025;30(2):162.","journal-title":"Exp Ther Med"},{"key":"10009_CR120","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.103029","volume":"80","author":"J Bezin","year":"2025","unstructured":"Bezin J, Benard-Laribiere A, Hucteau E, Tournier M, Montastruc F, Pariente A, et al. Suicide and suicide attempt in users of GLP-1 receptor agonists: a nationwide case-time-control study. EClinicalMedicine. 2025;80:103029.","journal-title":"EClinicalMedicine"},{"issue":"1","key":"10009_CR121","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.schres.2009.07.011","volume":"115","author":"GC Smith","year":"2009","unstructured":"Smith GC, Vickers MH, Cognard E, Shepherd PR. Clozapine and quetiapine acutely reduce glucagon-like peptide-1 production and increase glucagon release in obese rats: implications for glucose metabolism and food choice behaviour. Schizophr Res. 2009;115(1):30\u201340.","journal-title":"Schizophr Res"},{"issue":"2","key":"10009_CR122","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1007\/s11011-014-9591-7","volume":"30","author":"AN Sharma","year":"2015","unstructured":"Sharma AN, Ligade SS, Sharma JN, Shukla P, Elased KM, Lucot JB. GLP-1 receptor agonist liraglutide reverses long-term atypical antipsychotic treatment associated behavioral depression and metabolic abnormalities in rats. Metab Brain Dis. 2015;30(2):519\u201327.","journal-title":"Metab Brain Dis"},{"issue":"5","key":"10009_CR123","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1177\/0269881118756061","volume":"32","author":"I Babic","year":"2018","unstructured":"Babic I, Gorak A, Engel M, Sellers D, Else P, Osborne AL, et al. Liraglutide prevents metabolic side-effects and improves recognition and working memory during antipsychotic treatment in rats. J Psychopharmacol. 2018;32(5):578\u201390.","journal-title":"J Psychopharmacol"},{"key":"10009_CR124","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2024.116763","volume":"176","author":"K Horska","year":"2024","unstructured":"Horska K, Kucera J, Drazanova E, Kuzminova G, Amchova P, Hrickova M, et al. Potent synergistic effects of dulaglutide and food restriction in prevention of olanzapine-induced metabolic adverse effects in a rodent model. Biomed Pharmacother. 2024;176:116763.","journal-title":"Biomed Pharmacother"},{"issue":"1","key":"10009_CR125","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1002\/oby.22666","volume":"28","author":"T Liao","year":"2020","unstructured":"Liao T, Zhang SL, Yuan X, Mo WQ, Wei F, Zhao SN, et al. Liraglutide lowers body weight set point in DIO rats and its relationship with hypothalamic microglia activation. Obesity. 2020;28(1):122\u201331.","journal-title":"Obesity"},{"key":"10009_CR126","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2025.117091","volume":"240","author":"Y He","year":"2025","unstructured":"He Y, Wang L, Cao T, Jiao S, Chen H, Lin C, et al. Liraglutide attenuates clozapine-induced mitochondrial dysfunction and improves energy metabolism in the brain of rats. Biochem Pharmacol. 2025;240:117091.","journal-title":"Biochem Pharmacol"},{"issue":"12","key":"10009_CR127","doi-asserted-by":"publisher","first-page":"2544","DOI":"10.1038\/s41366-025-01885-4","volume":"49","author":"JS Varghese","year":"2025","unstructured":"Varghese JS, Goldsmith DR, Cotes RO, Ravikumar V, Ali MK, Pasquel FJ. Weight change from incretin-based weight loss medications across categories of second-generation antipsychotics. Int J Obes (Lond). 2025;49(12):2544\u20138.","journal-title":"Int J Obes (Lond)"},{"key":"10009_CR128","doi-asserted-by":"crossref","unstructured":"Hejdak D, Razzak AN, Sun L, Rahman M, Jha P. Interaction of semaglutide and ziprasidone in a patient with schizophrenia: a case report. Cureus. 2024;16(4):e59319.","DOI":"10.7759\/cureus.59319"},{"key":"10009_CR129","doi-asserted-by":"publisher","DOI":"10.1016\/j.peptides.2023.171003","volume":"165","author":"A Novikoff","year":"2023","unstructured":"Novikoff A, Muller TD. The molecular pharmacology of glucagon agonists in diabetes and obesity. Peptides. 2023;165:171003.","journal-title":"Peptides"},{"issue":"5","key":"10009_CR130","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1016\/j.cmet.2025.03.011","volume":"37","author":"E Ravussin","year":"2025","unstructured":"Ravussin E, Sanchez-Delgado G, Martin CK, Beyl RA, Greenway FL, O\u2019Farrell LS, et al. Tirzepatide did not impact metabolic adaptation in people with obesity, but increased fat oxidation. Cell Metab. 2025;37(5):1060\u201374. e4.","journal-title":"Cell Metab"},{"issue":"5","key":"10009_CR131","doi-asserted-by":"publisher","first-page":"2844","DOI":"10.1111\/dom.16294","volume":"27","author":"A Zhang","year":"2025","unstructured":"Zhang A, Liu Q, Xiong Y, Li J, Xu Y, Song H, et al. Tirzepatide reduces body weight by increasing fat utilization via the central nervous system-adipose tissue axis in male mice. Diabetes Obes Metab. 2025;27(5):2844\u201356.","journal-title":"Diabetes Obes Metab"},{"key":"10009_CR132","doi-asserted-by":"publisher","first-page":"171138","DOI":"10.1016\/j.peptides.2023.171138","volume":"173","author":"R Spezani","year":"2024","unstructured":"Spezani R, Marinho TS, Reis TS, Aguila MB, Mandarim-de-Lacerda CA. Cotadutide (GLP-1\/Glucagon dual receptor agonist) modulates hypothalamic orexigenic and anorexigenic neuropeptides in obese mice. Peptides. 2024;173:171138.","journal-title":"Peptides"},{"issue":"3","key":"10009_CR133","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1038\/s41573-021-00337-8","volume":"21","author":"TD Muller","year":"2022","unstructured":"Muller TD, Bluher M, Tschop MH, DiMarchi RD. Anti-obesity drug discovery: advances and challenges. Nat Rev Drug Discov. 2022;21(3):201\u201323.","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"10009_CR134","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1007\/s13679-024-00598-5","volume":"14","author":"L Moss","year":"2025","unstructured":"Moss L, Laudenslager M, Steffen KJ, Sockalingam S, Coughlin JW. Antidepressants and weight gain: an update on the evidence and clinical implications. Curr Obes Rep. 2025;14(1):2.","journal-title":"Curr Obes Rep"},{"key":"10009_CR135","doi-asserted-by":"publisher","first-page":"1491417","DOI":"10.3389\/fpsyt.2024.1491417","volume":"15","author":"I Fitzgerald","year":"2024","unstructured":"Fitzgerald I, Sahm LJ, Ni Dhubhlaing C, O\u2019Dwyer S, O\u2019Connell J, Torrens J, et al. Metformin in the management of antipsychotic-induced weight gain - why the \u2018weight\u2019? Front Psychiatry. 2024;15:1491417.","journal-title":"Front Psychiatry"},{"issue":"1","key":"10009_CR136","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-023-01309-7","volume":"8","author":"T Li","year":"2023","unstructured":"Li T, Yang Y, Qi H, Cui W, Zhang L, Fu X, et al. CRISPR\/Cas9 therapeutics: progress and prospects. Signal Transduct Target Ther. 2023;8(1):36.","journal-title":"Signal Transduct Target Ther"},{"key":"10009_CR137","doi-asserted-by":"crossref","unstructured":"Wang L, De Solis AJ, Goffer Y, Birkenbach KE, Engle SE, Tanis R et al. Ciliary gene RPGRIP1L is required for hypothalamic arcuate neuron development. JCI Insight. 2019;4(3):e123337.","DOI":"10.1172\/jci.insight.123337"},{"key":"10009_CR138","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2021.101218","volume":"49","author":"TL Stincic","year":"2021","unstructured":"Stincic TL, Bosch MA, Hunker AC, Juarez B, Connors AM, Zweifel LS, et al. CRISPR knockdown of Kcnq3 attenuates the M-current and increases excitability of NPY\/AgRP neurons to alter energy balance. Mol Metab. 2021;49:101218.","journal-title":"Mol Metab"},{"issue":"7702","key":"10009_CR139","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1038\/s41586-018-0049-7","volume":"556","author":"J Xu","year":"2018","unstructured":"Xu J, Bartolome CL, Low CS, Yi X, Chien CH, Wang P, et al. Genetic identification of leptin neural circuits in energy and glucose homeostases. Nature. 2018;556(7702):505\u20139.","journal-title":"Nature"},{"key":"10009_CR140","doi-asserted-by":"crossref","unstructured":"Vranceanu M, Filip L, Heghes SC, de Lorenzo D, Cozma-Petrut A, Ghitea TC et al. Genes involved in susceptibility to obesity and emotional eating behavior in a Romanian population. Nutrients. 2024;16(16):2652.","DOI":"10.3390\/nu16162652"},{"issue":"2","key":"10009_CR141","doi-asserted-by":"publisher","first-page":"71","DOI":"10.9758\/cpn.2012.10.2.71","volume":"10","author":"GP Reynolds","year":"2012","unstructured":"Reynolds GP. Pharmacogenetic aspects of antipsychotic Drug-induced weight gain - a critical review. Clin Psychopharmacol Neurosci. 2012;10(2):71\u20137.","journal-title":"Clin Psychopharmacol Neurosci"},{"issue":"1","key":"10009_CR142","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/1744-9081-10-35","volume":"10","author":"X Song","year":"2014","unstructured":"Song X, Pang L, Feng Y, Fan X, Li X, Zhang W, et al. Fat-mass and obesity-associated gene polymorphisms and weight gain after risperidone treatment in first episode schizophrenia. Behav Brain Funct. 2014;10(1):35.","journal-title":"Behav Brain Funct"},{"issue":"10","key":"10009_CR143","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1007\/s13238-019-0635-y","volume":"10","author":"Z Wang","year":"2019","unstructured":"Wang Z, Yang L, Qu S, Zhang C. CRISPR-mediated gene editing to rescue haploinsufficient obesity syndrome. Protein Cell. 2019;10(10):705\u20138.","journal-title":"Protein Cell"},{"issue":"1","key":"10009_CR144","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0008771","volume":"5","author":"YC Tung","year":"2010","unstructured":"Tung YC, Ayuso E, Shan X, Bosch F, O\u2019Rahilly S, Coll AP, et al. Hypothalamic-specific manipulation of Fto, the ortholog of the human obesity gene FTO, affects food intake in rats. PLoS One. 2010;5(1):e8771.","journal-title":"PLoS One"},{"issue":"8055","key":"10009_CR145","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1038\/s41586-024-08504-8","volume":"639","author":"JA Tadross","year":"2025","unstructured":"Tadross JA, Steuernagel L, Dowsett GKC, Kentistou KA, Lundh S, Porniece M, et al. A comprehensive spatio-cellular map of the human hypothalamus. Nature. 2025;639(8055):708\u201316.","journal-title":"Nature"},{"issue":"9","key":"10009_CR146","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1001\/archgenpsychiatry.2012.191","volume":"69","author":"AK Malhotra","year":"2012","unstructured":"Malhotra AK, Correll CU, Chowdhury NI, Muller DJ, Gregersen PK, Lee AT, et al. Association between common variants near the melanocortin 4 receptor gene and severe antipsychotic drug-induced weight gain. Arch Gen Psychiatry. 2012;69(9):904\u201312.","journal-title":"Arch Gen Psychiatry"},{"issue":"13","key":"10009_CR147","doi-asserted-by":"publisher","first-page":"2324","DOI":"10.1016\/j.cell.2022.05.003","volume":"185","author":"K Kato","year":"2022","unstructured":"Kato K, Zhou W, Okazaki S, Isayama Y, Nishizawa T, Gootenberg JS, et al. Structure and engineering of the type III-E CRISPR-Cas7-11 effector complex. Cell. 2022;185(13):2324\u2013e3716.","journal-title":"Cell"},{"issue":"2","key":"10009_CR148","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.gendis.2017.04.001","volume":"4","author":"CS Lee","year":"2017","unstructured":"Lee CS, Bishop ES, Zhang R, Yu X, Farina EM, Yan S, et al. Adenovirus-mediated gene delivery: potential applications for gene and cell-based therapies in the new era of personalized medicine. Genes & Dis. 2017;4(2):43\u201363.","journal-title":"Genes & Dis"},{"issue":"5","key":"10009_CR149","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1038\/s41573-019-0012-9","volume":"18","author":"D Wang","year":"2019","unstructured":"Wang D, Tai PWL, Gao G. Adeno-associated virus vector as a platform for gene therapy delivery. Nat Rev Drug Discov. 2019;18(5):358\u201378.","journal-title":"Nat Rev Drug Discov"},{"issue":"5","key":"10009_CR150","doi-asserted-by":"publisher","first-page":"2192","DOI":"10.1016\/j.ymthe.2025.03.062","volume":"33","author":"NR Hackett","year":"2025","unstructured":"Hackett NR, Crystal RG. Four decades of adenovirus gene transfer vectors: history and current use. Mol Ther. 2025;33(5):2192\u2013204.","journal-title":"Mol Ther"},{"key":"10009_CR151","doi-asserted-by":"crossref","unstructured":"Watanabe M, Nishikawaji Y, Kawakami H, Kosai KI. Adenovirus Biology, Recombinant adenovirus, and adenovirus usage in gene therapy. Viruses. 2021;13(12):2502.","DOI":"10.3390\/v13122502"},{"issue":"11","key":"10009_CR152","doi-asserted-by":"publisher","first-page":"2213","DOI":"10.2337\/db17-1538","volume":"67","author":"P Seoane-Collazo","year":"2018","unstructured":"Seoane-Collazo P, Roa J, Rial-Pensado E, Linares-Pose L, Beiroa D, Ruiz-Pino F, et al. SF1-Specific AMPKalpha1 deletion protects against Diet-Induced obesity. Diabetes. 2018;67(11):2213\u201326.","journal-title":"Diabetes"},{"issue":"3","key":"10009_CR153","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1210\/en.2014-1611","volume":"156","author":"PB Martinez de Morentin","year":"2015","unstructured":"Martinez de Morentin PB, Lage R, Gonzalez-Garcia I, Ruiz-Pino F, Martins L, Fernandez-Mallo D, et al. Pregnancy induces resistance to the anorectic effect of hypothalamic malonyl-CoA and the thermogenic effect of hypothalamic AMPK Inhibition in female rats. Endocrinology. 2015;156(3):947\u201360.","journal-title":"Endocrinology"},{"issue":"8","key":"10009_CR154","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1016\/j.molmed.2023.04.006","volume":"29","author":"S Mukherjee","year":"2023","unstructured":"Mukherjee S, Dieguez C, Ferno J, Lopez M. Obesity wars: hypothalamic sEVs a new hope. Trends Mol Med. 2023;29(8):622\u201334.","journal-title":"Trends Mol Med"},{"issue":"11","key":"10009_CR155","doi-asserted-by":"publisher","first-page":"2754","DOI":"10.1093\/annonc\/mdx493","volume":"28","author":"MH Voss","year":"2017","unstructured":"Voss MH, Hussain A, Vogelzang N, Lee JL, Keam B, Rha SY, et al. A randomized phase II trial of CRLX101 in combination with bevacizumab versus standard of care in patients with advanced renal cell carcinoma. Ann Oncol. 2017;28(11):2754\u201360.","journal-title":"Ann Oncol"},{"issue":"1","key":"10009_CR156","doi-asserted-by":"publisher","first-page":"8","DOI":"10.2174\/157340711795163866","volume":"7","author":"C Young","year":"2011","unstructured":"Young C, Schluep T, Hwang J, Eliasof S. CRLX101 (formerly IT-101)-a novel nanopharmaceutical of camptothecin in clinical development. Curr Bioact Compd. 2011;7(1):8\u201314.","journal-title":"Curr Bioact Compd"},{"issue":"1","key":"10009_CR157","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1002\/cre2.512","volume":"8","author":"Z Golestannejad","year":"2022","unstructured":"Golestannejad Z, Khozeimeh F, Mehrasa M, Mirzaeei S, Sarfaraz D. A novel drug delivery system using acyclovir nanofiber patch for topical treatment of recurrent herpes labialis: a randomized clinical trial. Clin Exp Dent Res. 2022;8(1):184\u201390.","journal-title":"Clin Exp Dent Res"},{"issue":"1","key":"10009_CR158","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1038\/s41467-023-44416-3","volume":"15","author":"Y Lu","year":"2024","unstructured":"Lu Y, Luo Z, Zhou H, Shi Y, Zhu Y, Guo X, et al. A nanoemulsion targeting adipose hypertrophy and hyperplasia shows anti-obesity efficiency in female mice. Nat Commun. 2024;15(1):72.","journal-title":"Nat Commun"},{"issue":"8","key":"10009_CR159","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.1166\/jbn.2015.2082","volume":"11","author":"FA Dimer","year":"2015","unstructured":"Dimer FA, Pigatto MC, Boque CA, Pase CS, Roversi K, Pohlmann AR, et al. Nanoencapsulation improves relative bioavailability and antipsychotic effect of olanzapine in rats. J Biomed Nanotechnol. 2015;11(8):1482\u201393.","journal-title":"J Biomed Nanotechnol"},{"key":"10009_CR160","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.ejps.2017.03.050","volume":"104","author":"E Joseph","year":"2017","unstructured":"Joseph E, Reddi S, Rinwa V, Balwani G, Saha R. Design and in vivo evaluation of solid lipid nanoparticulate systems of olanzapine for acute phase schizophrenia treatment: investigations on antipsychotic potential and adverse effects. Eur J Pharm Sci. 2017;104:315\u201325.","journal-title":"Eur J Pharm Sci"},{"issue":"Pt 4","key":"10009_CR161","doi-asserted-by":"publisher","first-page":"134385","DOI":"10.1016\/j.ijbiomac.2024.134385","volume":"277","author":"A Lofts","year":"2024","unstructured":"Lofts A, Campea MA, Winterhelt E, Rigg N, Rivera NP, Macdonald C, et al. In situ-gelling hydrophobized starch nanoparticle-based nanoparticle network hydrogels for the effective delivery of intranasal olanzapine to treat brain disorders. Int J Biol Macromol. 2024;277(Pt 4):134385.","journal-title":"Int J Biol Macromol"},{"issue":"1","key":"10009_CR162","doi-asserted-by":"publisher","first-page":"5502","DOI":"10.1038\/s41598-022-09541-x","volume":"12","author":"M He","year":"2022","unstructured":"He M, Yao J, Zhang Z, Zhang Y, Chen R, Gu Z, et al. Gold nanoclusters eliminate obesity induced by antipsychotics. Sci Rep. 2022;12(1):5502.","journal-title":"Sci Rep"},{"key":"10009_CR163","doi-asserted-by":"crossref","unstructured":"Mohapatra SS, Frisina RD, Mohapatra S, Sneed KB, Markoutsa E, Wang T et al. Advances in translational nanotechnology: challenges and opportunities. Appl Sci (Basel). 2020;10(14):4881.","DOI":"10.3390\/app10144881"},{"issue":"9","key":"10009_CR164","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1016\/j.cmet.2021.08.002","volume":"33","author":"C Crewe","year":"2021","unstructured":"Crewe C, Funcke JB, Li S, Joffin N, Gliniak CM, Ghaben AL, et al. Extracellular vesicle-based interorgan transport of mitochondria from energetically stressed adipocytes. Cell Metab. 2021;33(9):1853\u201368. e11.","journal-title":"Cell Metab"},{"key":"10009_CR165","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.trsl.2021.01.006","volume":"239","author":"T Camino","year":"2022","unstructured":"Camino T, Lago-Baameiro N, Bravo SB, Molares-Vila A, Sueiro A, Couto I, et al. Human obese white adipose tissue sheds depot-specific extracellular vesicles and reveals candidate biomarkers for monitoring obesity and its comorbidities. Transl Res. 2022;239:85\u2013102.","journal-title":"Transl Res"},{"issue":"3","key":"10009_CR166","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1016\/j.cell.2018.09.005","volume":"175","author":"C Crewe","year":"2018","unstructured":"Crewe C, Joffin N, Rutkowski JM, Kim M, Zhang F, Towler DA, et al. An endothelial-to-adipocyte extracellular vesicle axis governed by metabolic state. Cell. 2018;175(3):695\u2013708 e13.","journal-title":"Cell"},{"issue":"10","key":"10009_CR167","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1038\/s42255-021-00467-8","volume":"3","author":"E Milbank","year":"2021","unstructured":"Milbank E, Dragano NRV, Gonzalez-Garcia I, Garcia MR, Rivas-Limeres V, Perdomo L, et al. Small extracellular vesicle-mediated targeting of hypothalamic AMPKalpha1 corrects obesity through BAT activation. Nat Metab. 2021;3(10):1415\u201331.","journal-title":"Nat Metab"},{"key":"10009_CR168","doi-asserted-by":"publisher","first-page":"155350","DOI":"10.1016\/j.metabol.2022.155350","volume":"139","author":"E Milbank","year":"2023","unstructured":"Milbank E, Dragano N, Vidal-Gomez X, Rivas-Limeres V, Garrido-Gil P, Wertheimer M, et al. Small extracellular vesicle targeting of hypothalamic AMPKalpha1 promotes weight loss in leptin receptor deficient mice. Metabolism. 2023;139:155350.","journal-title":"Metabolism"},{"issue":"9","key":"10009_CR169","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1080\/17512433.2022.2117152","volume":"15","author":"G Zhao","year":"2022","unstructured":"Zhao G, Zhang Q, Wu F, Yin S, Xie Y, Liu H. Comparison of weight loss and adverse events of obesity drugs in children and adolescents: a systematic review and meta-analysis. Expert Rev Clin Pharmacol. 2022;15(9):1119\u201325.","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"4","key":"10009_CR170","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1210\/jc.2015-3754","volume":"101","author":"VR Aroda","year":"2016","unstructured":"Aroda VR, Edelstein SL, Goldberg RB, Knowler WC, Marcovina SM, Orchard TJ, et al. Long-term Metformin use and vitamin B12 deficiency in the Diabetes Prevention Program Outcomes Study. J Clin Endocrinol Metab. 2016;101(4):1754\u201361.","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"10009_CR171","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1111\/dom.14979","volume":"25","author":"WJ Valentine","year":"2023","unstructured":"Valentine WJ, Hoog M, Mody R, Belger M, Pollock R. Long-term cost-effectiveness analysis of Tirzepatide versus semaglutide 1.0 mg for the management of type 2 diabetes in the United States. Diabetes Obes Metab. 2023;25(5):1292\u2013300.","journal-title":"Diabetes Obes Metab"}],"container-title":["Reviews in Endocrine and Metabolic Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11154-025-10009-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11154-025-10009-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11154-025-10009-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T15:37:24Z","timestamp":1781624244000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11154-025-10009-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,23]]},"references-count":171,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["10009"],"URL":"https:\/\/doi.org\/10.1007\/s11154-025-10009-2","relation":{},"ISSN":["1389-9155","1573-2606"],"issn-type":[{"value":"1389-9155","type":"print"},{"value":"1573-2606","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,23]]},"assertion":[{"value":"28 November 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 December 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical trial number"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}